Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
The Medicines Co. Continues to Focus on Pipeline Development

The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.

MDCO : 35.44 (+1.40%)
MNK : 34.83 (-0.09%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions

Bayer (BAYRY) remains focused on developing its pipeline and acquisitions in order to boost its portfolio.

BAYRY : 33.0300 (-0.09%)
REGN : 432.72 (-0.17%)
MON : 119.77 (+0.31%)
ALXN : 142.82 (-0.07%)
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

ALNY : 113.80 (+0.78%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
ALXN : 142.82 (-0.07%)
How is the Age-Related Macular Degeneration Space Faring Now?

The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

AGN : 204.65 (+0.98%)
OPHT : 2.69 (unch)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
REGN : 432.72 (-0.17%)
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status

ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.

PDLI : 3.17 (-3.06%)
PRQR : 6.20 (+7.83%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Teva/Nuvelution to Speed Up Development of Austedo in US

Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.

HLUYY : 60.1180 (+2.89%)
TEVA : 17.19 (+0.23%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

JNJ : 131.39 (-0.27%)
REGN : 432.72 (-0.17%)
ALKS : 50.37 (+0.06%)
ALXN : 142.82 (-0.07%)
Pluristem's Ischemia Candidate Gets Fast Track Designation

Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.

PDLI : 3.17 (-3.06%)
REGN : 432.72 (-0.17%)
PSTI : 1.54 (-1.28%)
ALXN : 142.82 (-0.07%)
Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group

Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group

AMAT : 47.77 (+1.31%)
VNTV : 71.93 (-0.24%)
CBG : 37.18 (-0.03%)
HAS : 96.14 (+1.37%)
REGN : 432.72 (-0.17%)
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU

Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.

INVA : 13.78 (+2.15%)
REGN : 432.72 (-0.17%)
GSK : 40.58 (+0.62%)
ALXN : 142.82 (-0.07%)
5 Top Stocks with Impressive Sales Growth Worth Betting On

Steady sales growth is the key to survival for any business. Also, it is an important tool for making investment decisions.

AMAT : 47.77 (+1.31%)
VNTV : 71.93 (-0.24%)
CBG : 37.18 (-0.03%)
HAS : 96.14 (+1.37%)
REGN : 432.72 (-0.17%)
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from the Phase 3 CAFÉ study of DUPIXENT® (dupilumab) in adults with moderate-to-severe atopic dermatitis (AD)...

SAN : 6.83 (+0.59%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study

Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.

JNJ : 131.39 (-0.27%)
REGN : 432.72 (-0.17%)
PFE : 35.96 (-0.03%)
ALXN : 142.82 (-0.07%)
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

LLY : 83.91 (+0.70%)
INCY : 110.85 (-3.65%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote

Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.

LGND : 135.55 (-0.19%)
REGN : 432.72 (-0.17%)
GSK : 40.58 (+0.62%)
ALXN : 142.82 (-0.07%)
Alexion (ALXN) Reports Interim Results for Soliris Study

Alexion (ALXN) announced results from an interim analysis of an ongoing phase III REGAIN study of Soliris. The study showed sustained treatment benefits of Soliris treatment for patients with refractory...

ACAD : 37.59 (-0.11%)
REGN : 432.72 (-0.17%)
ADRO : 10.80 (-1.82%)
ALXN : 142.82 (-0.07%)
Stocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle Genetics

If you want a Stock Review on PBYI, REGN, SRPT, or SGEN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, September 13, 2017, the...

SRPT : 45.17 (-4.10%)
PBYI : 104.50 (-0.29%)
SGEN : 52.48 (+0.23%)
REGN : 432.72 (-0.17%)
Alexion to Restructure Operations, to Lower Headcount by 20%

Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.

ABUS : 6.55 (-6.43%)
REGN : 432.72 (-0.17%)
ADRO : 10.80 (-1.82%)
ALXN : 142.82 (-0.07%)
Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data

Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.

VRTX : 151.26 (-0.53%)
KURA : 12.00 (-3.23%)
SAGE : 62.90 (-3.22%)
ABBV : 87.48 (+0.08%)
REGN : 432.72 (-0.17%)
ICPT : 61.59 (-16.43%)
ALXN : 142.82 (-0.07%)
Smart Medical Device Could Save Millions of Lives

Stroke and heart diseases cost the U.S. nearly $1 billion every day in medical costs and lost productivity, so when a small-cap biotech company finally starts releasing validation news for a medical device...

EXAS : 45.96 (+2.13%)
CLBS : 3.80 (+0.26%)
SHPG : 155.09 (-0.17%)
REGN : 432.72 (-0.17%)

Van Meerten Stock Picks

5 Great Mid Caps
Today I wanted to find 5 Mid Cap stocks that had a high gain over the last year and continue to have current momentum.
DAN +0.41 , IPGP +4.16 , TEX -0.46 , NVR +29.06 , TTWO +1.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.14% ) this morning are down -0.09% on heightened North Korean tensions after North Korean President Kim Jong Un promised the "highest level of hardline" countermeasures against the U.S.... Read More

Chart of the Day

Chart of the Day

Fiat Chrysler Automobiles (FCAU) is the Barchart Chart of the Day.  The international auto producer has a Trend Spotter buy signal, a Weighted Alpha of 190.70+ and gained 174.92% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures settled Friday with 2 to 3 1/2 cent gains, as Dec was 1 1/4 cent lower on the week. Rains over the next week could slow corn harvest in most of the WCB. Next Friday at 11:00 a.m. will be the release of the Sept 1 Grain Stocks report. The...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.